KR-20260062820-A - Composition for Preventing and Treating atherosclerosis, comprising graphene nanostructure

KR20260062820AKR 20260062820 AKR20260062820 AKR 20260062820AKR-20260062820-A

Abstract

The present invention relates to the use of graphene nanostructures, specifically to a composition for the improvement, prevention, or treatment of arteriosclerosis or related diseases comprising nano graphene oxide.

Inventors

강경선
김다현
공다솜

Assignees

서울대학교산학협력단
성신여자대학교 연구 산학협력단

Dates

Publication Date: 20260507
Application Date: 20250814
Priority Date: 20241028

Claims (8)

A pharmaceutical composition for the prevention or treatment of arteriosclerosis or arteriosclerosis-related diseases, comprising nano-sized graphene oxide as an active ingredient.
In Article 1, A pharmaceutical composition in which the above-mentioned nano-graphene oxide has a lateral length of 10 to 100 nm.
In Article 1, A pharmaceutical composition wherein the above-mentioned nano-graphene oxide contains 10 to 50 weight percent of oxygen.
In Article 1, A pharmaceutical composition wherein the above-mentioned arteriosclerosis-related disease is any one selected from the group consisting of cerebral softening, cerebral infarction, angina pectoris, myocardial infarction, heart failure, ischemic stroke, transient ischemic attack, peripheral artery disease, renal vascular hypertension, chronic kidney disease, vascular dementia, diabetic vascular complications, aortic aneurysm, vascular inflammation-related diseases, and metabolic diseases.
A food composition for improving or preventing arteriosclerosis or arteriosclerosis-related diseases, comprising nano-sized graphene oxide as an active ingredient.
In Article 5, A food composition in which the above-mentioned nano-graphene oxide has a lateral length of 10 to 100 nm.
In Article 5, A food composition in which the above-mentioned nano-graphene oxide contains 10 to 50 weight percent of oxygen.
In Article 5, A food composition wherein the above-mentioned arteriosclerosis-related disease is any one selected from the group consisting of cerebral softening, cerebral infarction, angina pectoris, myocardial infarction, heart failure, ischemic stroke, transient ischemic attack, peripheral artery disease, renal vascular hypertension, chronic kidney disease, vascular dementia, diabetic vascular complications, aortic aneurysm, vascular inflammation-related diseases, and metabolic diseases.

Description

Composition for Preventing and Treating atherosclerosis, comprising graphene nanostructure The present invention relates to the use of graphene nanostructures, specifically to a composition for the improvement, prevention, or treatment of arteriosclerosis or related diseases comprising nano graphene oxide. Atherosclerosis is a disease characterized by the accumulation of plaque, composed of fat, cholesterol, cellular debris, calcium, and fibrous material, on the inner walls of blood vessels, particularly arteries. This leads to the narrowing and hardening of vessels, obstructing blood flow. While hypertension, smoking, and a Western diet are known risk factors, the exact cause remains unknown. Although the accumulation of low-density lipoproteins (LDL) within blood vessels can be a direct cause of early-stage atherosclerosis, it is a pathological condition resulting from complex reactions involving inflammatory responses accompanied by complex interactions between blood vessels and immune cells, the infiltration of LDL cholesterol into the vessel walls, the formation of foam cells when oxidized LDL is phagocytosed by immune cells, and fibrosis. Furthermore, atherosclerosis is not considered a standalone disease but is known to serve as the pathophysiological central axis of systemic vascular disease. For example, cerebral arteriosclerosis is known to cause headaches, mental disorders, and cerebral softening, while coronary arteriosclerosis is known to cause angina pectoris, myocardial infarction, and heart failure. Furthermore, blood flow blockage due to atherosclerosis in the carotid and cerebral arteries causes ischemic stroke, transient ischemic attack, peripheral artery disease (PAD) resulting from reduced blood flow to the lower extremities, and irreversible tissue necrosis; meanwhile, arteriosclerosis in the arteries leading to the kidneys is known to cause renal vascular hypertension and chronic kidney disease (CKD). In addition, vascular dementia, diabetic vascular complications, and aortic aneurysms resulting from reduced cerebral blood flow are also known to be diseases that can occur due to arteriosclerosis. According to the announcement by the National Statistical Office of Korea, the mortality rate associated with arteriosclerosis showed a rapidly increasing trend, rising from 20% in 1995 to 73% in 2000 (Korean Patent Publication 10-2007-0115514). The drugs currently used for arteriosclerosis are mainly statin-class drugs that target cholesterol, and their therapeutic effects on other complex symptoms of arteriosclerosis are merely incidental. Therefore, if a drug is developed that exhibits a complex therapeutic effect on various pathological conditions of arteriosclerosis, it is expected that arteriosclerosis can be effectively improved, prevented, or treated, thereby significantly reducing the incidence and mortality rates of various diseases caused by it. FIG. 1 is a drawing showing one example of measuring the height and side dimensions of an NGO according to one embodiment of the present invention. FIG. 2 is a drawing showing one example of measuring the inter-floor distance of an NGO according to one embodiment of the present invention. FIG. 3 is a diagram showing one example of confirming the Raman spectrum of an NGO according to one embodiment of the present invention. FIG. 4 is a diagram showing an example of analyzing an NGO according to one embodiment of the present invention using Fourier transform infrared spectroscopy. FIG. 5 is a diagram showing an example of analyzing an NGO according to one embodiment of the present invention using X-ray photoelectron spectroscopy. Figure 6 is a diagram showing the results of confirming the degree of cytotoxicity of an NGO according to one embodiment of the present invention. FIG. 7 is a diagram showing the results of confirming the degree of Blood Vessel Organoid infiltration of an NGO according to one embodiment of the present invention. The white line in the diagram represents 100 μm. Figure 8 is a diagram showing the results of confirming the effect of NGO on the secretion of inflammatory cytokines according to one embodiment of the present invention using quantitative real-time polymerase chain reaction. Figure 9 is a diagram showing the results of confirming the effect of NGO on an attachment molecule and iNOS according to one embodiment of the present invention by immunofluorescence staining. The white line in the diagram represents 100 μm. Figure 10 is a diagram showing the results of confirming the degree of accumulation of CFDA-labeled monocyte cells by green fluorescence to determine whether an NGO according to one embodiment of the present invention can alleviate an arteriosclerosis phenotype. Figure 11 is a diagram showing the results of confirming by immunohistochemistry whether an NGO according to one embodiment of the present invention can reduce ROS (reactive oxygen species). FIG. 12 is a diagram showing the results of confirmi